Vis børsmeldingen
2026 and approved by an extraordinary general meeting of Aker BioMarine on
August 17, 2026 (the “Merger”).
All conditions for the Merger have now been fulfilled and the Merger is
expected to be completed after close of trading on October 1, 2026.
Shareholders in Aker BioMarine (other than MergerCo) will for each Aker
BioMarine share held as of the expiry of October 1, 2026 (as registered in
Euronext Securities Oslo (VPS) on October 5, 2026 (the record date) receive
merger consideration in the form of 0.0706 shares in Aker, plus a cash amount
of NOK 21 per share, as further regulated in the merger plan for the Merger.
Aker will settle the share portion of the Merger consideration with a
combination of treasury shares and shares borrowed from Aker’s largest
shareholder, TRG Holding AS, as announced on July 17, 2026. Accordingly, no
new shares will be issued by Aker in connection with completion of the Merger.
For further information on the key dates of the Merger, please see the stock
exchange announcement from Aker BioMarine published on September 30, 2026.
Fractions of Aker consideration shares will not be allotted in the Merger. For
each Aker BioMarine shareholder the number of Aker shares will be rounded down
to each whole number, or to zero shares. Excess shares, which because of this
round down will not be allotted to eligible shareholders, will be issued to
and sold by an appointed investment bank or other third party according to
instructions from Aker at the expense and risk of the beneficiaries, with a
proportionate distribution of net sales proceeds among the shareholders who
have the number of consideration shares rounded off.
-ENDS-
Investor contact:
Fredrik Berge, Head of Investor Relations
+47 45 03 20 90
fredrik.berge@akerasa.com
This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-09-30 07:01 CEST.
Kilde
